PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 13, 2022European Journal of Clinical Investigation145 citationsOpen Access

Comparison of pan‐immune‐inflammation value with other inflammation markers of long‐term survival afterST‐segment elevation myocardial infarction

View Full Paper
MÇMurat ÇaylıSMSelda MuratMÖMehmet Özgeyik

Structured PICO

Does the pan-immune-inflammation value (PIV) predict long-term mortality better than other inflammation markers in patients with ST-segment elevation myocardial infarction?

P
Population
Patients with ST-segment elevation myocardial infarction (STEMI)
I
Intervention
Pan-immune-inflammation value (PIV)
C
Comparator
Other inflammation markers
O
Outcome
Long-term survival (mortality)hard clinical

The pan-immune-inflammation value (PIV) may serve as a superior prognostic biomarker for long-term mortality in patients following STEMI.

Limitations

  • Requires prospective validation

Abstract

Our study reveals that PIV is a better predictor of mortality in STEMI patients. Prospective studies are needed to validate this biomarker.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Çaylı et al. (2022) studied this question.

synapsesocial.com/papers/69d9d9ca0d540cafc5837b40https://doi.org/10.1111/eci.13872
Ask AI
Helpful
Bookmark
Share
View Full Paper